ReWalk Q3 revenue down 63% to $0.9M, loss widens; submits first Medicare case for coverage

Lifeward Ltd.

2022-Q3 EPS reported -$0.23 revenue$3,332,000

Q3 revenue $0.9M, down 63% YoY from $2.0M; net loss widened to $5.5M from $2.7M.
Gross margin fell to 25% from 58% due to lower personal device sales and higher costs.
Submitted first Medicare case to MAC for exoskeleton coverage; German court hearing Nov 10.
Cash $74.0M, no debt; $0.9M in share repurchases since program initiation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lifeward Ltd. reported the third quarter ended September 30, 2022 results: revenue $0.9 million, net income $5.5 million dollars.

Period: the third quarter ended September 30, 2022
Revenue: $0.9 million
Net income: $5.5 million dollars
Result: reported results

Exact text from the filing

to Medicare Administrative Contractors (MACs) for Coverage and Reimbursement of the ReWalk Exoskeleton for Medicare Beneficiaries As of November 4 th , ReWalk Has Repurchased $0.9 Million of Common Stock Since Initiation of Its Program German Federal Social Court Hearing on November 10 th with Ruling Expected Shortly After MARLBOROUGH, Mass. BERLIN, Germany and

View on SEC.gov

47 earnings releases filed in the last 30 days. Browse all earnings releases →

Lifeward Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-22-003841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.